TODAY -

A vaccine for COVID-19: So near and yet so far

Shobha Shukla *

 A vaccine for COVID-19: So near and yet so far



With the numbers of those infected with COVID-19 (SARS-CoV-2) escalating everyday globally we are indeed wading through turbulent waters with no end at sight. Scientists around the world are literally burning the midnight oil, searching frantically for a treatment to rid the world of this pandemic. It is a race between humans and the virus.

And although it is too early to predict anything, their efforts for developing a vaccine have met with some initial successes, with 5 candidate vaccines having entered phase-3 of their clinical trials. And as we wait with bated breath for the magic vaccine, a historic moment has already set in with the large scale manufacturing of some of these vaccines already begun, including in India.

saving human lives has primacy over money

This is an unprecedented move - to start producing large quantities of vaccines irrespective of the final outcome of the trials. It is a calculated risk that philanthropic organisations and some governments are ready to take by giving precedence to saving human lives over losing money (in case the vaccine does not make it to the final milestone). It will ensure timely and large-scale availability of doses in case that particular vaccine is successful.

AZD1222

One such candidate vaccine is AZD1222 that is being developed jointly by the University of Oxford and AstraZeneca. The Pune-based Serum Institute of India, the largest vaccine manufacturer in the world, that has entered into a manufacturing partnership with AstraZeneca, has committed to manufacture 1 billion (100 crore) doses of this vaccine and has already commenced production.

"This is a big, yet deliverable, assurance for global health as India is already the biggest manufacturer and supplier of more than 60% different kinds of vaccines worldwide. It is vital to ensure that manufacturing of COVID-19 vaccine remains in countries like India so that the world can have access to cheap and affordable prevention against the dreaded virus, without delay by ensuring equitable distribution", said Dr Ishwar Gilada, senior infectious diseases expert, and Secretary General of Organized Medicine Academic Guild (OMAG). Dr Gilada is also the President of AIDS Society of India, and on the governing council of International AIDS Society (IAS).

India is also likely to participate in phase-3 clinical trial of AZD1222. As per a news report, Serum Institute of India said it will apply for a licence from the Indian regulator to start clinical trials of the vaccine in the country very soon.

Dr S Natarajan, President of Organised Medicine Academic Guild (OMAG) and a Padmashree awardee (among the highest civilian honours in the country) hoped that the Indian Government will play a proactive role and expedite clearance to conduct these trials in India. While cautioning that "the results of phase-3 clinical trial will be very important to decide the safety, effectiveness and roll-out of the vaccine for public health use", he conceded that the initial results of this study give hope and that India should be proud to be a part of this initiative.

The results of the Phase-1/2 trial of AZD1222 published in The Lancet, indicate no early safety concerns and no serious side effects by the vaccine in 1077 trial participants aged 18-55 years. The vaccine produced a dual immune response that lasted till at least 56 days after they were immunised. Not only did it produce antibodies, which are the immune system's natural response, but it also produced T-cells that directly kill virus infected cells and are said to last much longer in the human body as compared to the protective antibodies.

Large scale Phase-3 clinical trials are currently underway in the UK (8000 participants) and Brazil (5000 participants) and are due to start in USA (30,000 participants), South Africa (2000 participants) as well as in India (10,000 participants).

4 more vaccines entering phase-3: WHO

As per WHO, apart from AZD1222, their are 4 other vaccines (out of the 24 candidate vaccines currently in clinical evaluation stages) that have entered phase-3 clinical trials, after successfully completing phases-1 and 2 (phases 1 and 2 evaluate safety, immunogenicity and efficacy of the vaccine in a small number of trial participants while in phase-3 the safety, immunogenicity and effectiveness of the potential vaccine is tested in a broader population - often multicountry - over a longer period of time).

Three of these are by Chinese companies, and one is being developed by an American firm Moderna Inc in collaboration with the US government's National Institute of Allergy and Infectious Diseases (NIAID), part of National Institutes of Health (NIH).

US-based biotechnology company Moderna, supported by the National Institute of Allergy and Infectious Diseases (NIAID) is developing a potential coronavirus vaccine candidate mRNA-1273. In fact, Moderna was the first organization to start human trials of mRNA-1273 on March 16, 2020 - 5 days after WHO had termed COVID-19 as a pandemic. The initial phase-1/2 trial has shown promising results. Phase-3 trials are planned to begin this month (in July) on 30,000 participants in USA.

China's state-run Sinopharm Group Co is working on two COVID-19 vaccines being developed by its subsidiary China National Biotec Group Co. (CNBG). As reported by Bloomberg News, these two experimental vaccines are already being offered to employees of large state-owned companies who intend to travel overseas for work. Administering an investigational vaccine (that is still being evaluated in clinical trials) to people outside of the clinical trial protocol is unusual indeed. China National Biotec Group Co. (CNBG) is aiming to produce 200 million doses of inactivated COVID-19 vaccines a year.

China's Beijing-based Sinovac Biotech has also announced positive results from its Phase-1/2 clinical trials of its vaccine CoronaVac and will start phase-3 trials on 9,000 healthcare professionals working in COVID-19 specialised facilities in Brazil and on 4,200 healthcare workers of 7 COVID-19 dedicated hospitals in Bangladesh.

An ideal vaccine against SARS-CoV-2 (Severe Acute Respiratory Syndrome CoronaVirus-2) should be safe and effective after one or two vaccinations; provide protection for a minimum of 6 months and protect old and young alike, including immunocompromised individuals and those with co-morbidities.

Agrees Dr Ishwar Gilada that while phase-3 clinical trials move ahead for these and other vaccines in the pipeline, it is the duty of all the governments, including the Indian government, to be geared to ensure that scientific breakthroughs translate into public health gains without any unnecessary delays. Whenever a safe and effective vaccine for COVID-19 becomes available for public health use, we must have strong health systems and other regulatory mechanisms already in place to be able to deliver it to those most in need of it globally.

Never before the world has conducted a vaccine research so quickly without compromising safety or scientific integrity. It is important to know if a vaccine is safe, immunogenic and effective in protecting us against coronavirus - and - it is equally important to ensure that everyone of us, especially those more vulnerable, to get it as soon as possible.

Dr Anthony S Fauci, Director of National Institute of Allergy and Infectious Diseases (NIAID) had said: "What happens is that in the standard way of developing a vaccine, you don't jump to invest in the next step until you're pretty sure that the step you're in is working... Given the fact that we needed to do this as quickly as possible without sacrificing safety or scientific integrity, the federal government partnered with multiple of these companies and said, we're going to move fast and we're going to assume we're going to be successful. And if we are, we've saved several months. And if we're not, the only thing we've lost is money. But better lose money than lose lives by delaying the vaccine."


* Shobha Shukla wrote this article for e-pao.net
The writer is the founding Managing Editor of CNS (Citizen News Service) and is a noted gender justice advocate.
She is a former senior faculty of Loreto Convent College and current Coordinator of Asia Pacific Media Network to end TB & tobacco and prevent NCDs.
Follow her on Twitter @shobha1shukla)
This article was webcasted on July 25 2020 .



* Comments posted by users in this discussion thread and other parts of this site are opinions of the individuals posting them (whose user ID is displayed alongside) and not the views of e-pao.net. We strongly recommend that users exercise responsibility, sensitivity and caution over language while writing your opinions which will be seen and read by other users. Please read a complete Guideline on using comments on this website.




LATEST IN E-PAO.NET
  • Addressing the Zeliangrong question
  • COVID-19 Status 10 August: Govt of Manipur
  • Ramkashing, Sinneihoi, Aton: eMing
  • Naga Peace Process :: News Timeline
  • Women plug food supply gap during lockdown
  • NGO Studies (MAINS) program in South Korea
  • Initiate inquiry for Hospital refusal
  • Love in the Hard Times :: Poem
  • From cluster to local transmission
  • Negative remarks on positive activities
  • MK PB Singh, 1st CM & Mizo agitation
  • COVID-19 Status 9 August: Govt of Manipur
  • Azolla: An organic farmer's friend
  • Corona Came Calling... :: Poem
  • Manipur gi sakkhangbidraba yelhoumee
  • COVID-19 : Impact in Manipur :: News Timeline
  • Thousand questions to life but.. one answer
  • Time to take all into confidence
  • Yaoshang Thabal Chongba #2 : Gallery
  • COVID-19 Status 8 August: Govt of Manipur
  • Impact of Covid-19 on mobile phone users
  • International Day of Indigenous Peoples
  • A call against systematic inequalities
  • August Diary :: Poem
  • A tale of Friendships Unlocked !
  • A Nuclear Free Future
  • Stay positive on Northeast plan
  • Is MSPDCL taking advantage of COVID-19
  • Folk Dance @Republic Day #2 : Gallery
  • COVID-19 Status 7 August: Govt of Manipur
  • Written obituary :: Poem
  • Truth unearth by COVID-19 pandemic
  • Clarification from SKY Hospital
  • COVID-19: Orders - 7 Aug: Govt of Manipur
  • Children's psychology & lockdown intervention
  • No confidence & godfather
  • Death in childbirth in the 21st century !
  • Need for a suitable pandemic model
  • Phuba Khuman in Senapati dist #1 : Gallery
  • COVID-19 Status 6 August: Govt of Manipur
  • Thoubalphobia- Malemnganbi's Child Delivery
  • Why not establish veterinary college, Manipur
  • India-Myanmar Convergence :: Webinar
  • National Education Policy : A New Horizon
  • Wanted : Total figure of local transmission
  • Lets appreciates the thousands heroes
  • Become an Amateur Astronomer
  • COVID-19 Status 5 August: Govt of Manipur
  • BIG 17th call : Biotech Ignition Grant
  • Maya Kuki- 3 titles at IAWA India 2020
  • 2020 :: Poem
  • What is Intellectual Property Right (IPR)?
  • Art of running a coalition Govt
  • Traditional Raas Dance #3 : Gallery
  • COVID-19 Status 4 August: Govt of Manipur
  • 2 from Manipur clear Civil Services Exam
  • Education Policy: Prospects & Way Forward
  • Appeal to stop Chromite mining
  • Agri-enterprises for Atmanirbhar North-East
  • Changes to make-up during COVID-19
  • Time to act sensibly
  • Barricading or brainstorming?
  • Tarao Laimanai, Chandel #2 : Gallery
  • COVID-19 Status 3 August: Govt of Manipur
  • Ravi's take on China factor in NE Insurgency
  • Opportunities in post COVID days
  • Shifting of drug supply trend in Manipur
  • Hope in COVID Era !! :: Poem
  • Press Communique from NPF [3 Aug]
  • Stand on ST demand
  • Culturals @ Sangai Fest 2019 #3 : Gallery
  • COVID-19 Status 2 August: Govt of Manipur
  • Misinterpretation of Naga Political Settlement
  • Home returnees, unemployment & ILPS
  • NEP to adversely affect future of North-east
  • Conflicts of laws on Child Marriage & POSCO
  • His Stoic Endurance :: Poem
  • 'Declare relatives working in Naga movement'
  • Rise from July 1 to August 1
  • 'Zehara' - Manipuri Movie :: eRang Classic
  • COVID-19 Status 1 August: Govt of Manipur
  • CCC @ Khongnangkhong [Aug 1]: Gallery
  • Where are the men in family planning ?
  • Asymptomatic & Rapid Antigen Testing
  • Cosmic Lover :: Poem
  • Incremental benefit of cleaning Nambul River
  • Why only 5 Kg of rice to cardholders?
  • Imphal View from Nongmai Ching #1 : Gallery
  • COVID-19 Status 31 July : Govt of Manipur
  • Id-Ul-Azha celebrated by Meitei Pangal
  • COVID-19 & its detection strategy
  • Physical Education & Sports @ MU
  • Naming the COVID vaccine
  • Withdraw MoUs signed for mining
  • More deaths, more concern
  • Ailing Nambul River recovering
  • Dr TS Gangte: Pioneer of higher education
  • COVID-19 Status 30 July : Govt of Manipur
  • August Calendar for Year 2020 : Tools
  • Hand sanitizer @Kakching [Jul 29]: Gallery
  • The Killing Fields 2013-20 : News Timeline
  • Orders / Memo on 30 July : Govt of Manipur
  • National Education Policy 2020
  • A Golden Jubilee Reunion :: Poem
  • Employment options in Insurance Industry
  • The Political life of the State
  • Recording death tally at four
  • Hentak :: An indigenous Manipuri food
  • COVID-19 Status 29 July : Govt of Manipur
  • Enforcement of COVID-19 Guidelines
  • My Love :: Poem
  • LPG management and supply
  • International Faculty Development Program
  • High-end Forensic Geology in crime scenes
  • Covid-19: Impact in Manipur :: Photos/News..
  • Manipur on the map of COVID death
  • Checking corruption: greatest joke of the year
  • Imphal during lockdown [26 July] #2 : Gallery
  • COVID-19 Status 28 July : Govt of Manipur
  • Plantation is no less a serious business
  • COVID-19 : Impact on mobility of women
  • Appeal to stop Mining in Ukhrul, Kamjong..
  • Making sense of lockdown
  • Non-Discrimination in combating COVID-19
  • Zeiladjang @ Makuai, Tamenglong : Gallery
  • COVID-19 Status 27 July : Govt of Manipur
  • Chassad & the Question of Justice
  • Online Training program for Police Officer
  • Proposal of Online Education: Its impact
  • The walls of Roman Londinium
  • Reminiscence of coming :: Book Review
  • Seeking to set house in order
  • The dawn of a new-normalcy
  • Imphal during lockdown [26 July] #1 : Gallery
  • COVID-19 Status 26 July : Govt of Manipur
  • Delimitation amasung yelhoumee Meetei..
  • Investigative Journalism training conducted
  • Gas Balloons :: Poem
  • Career in insurance: Jobs for millions
  • Meet model teacher helping students
  • Understanding total figure of 2212
  • Manipur Art Fest 2019 #1 : Gallery
  • COVID-19 Status 25 July : Govt of Manipur
  • PM calls for Vocal for Local to Manipur
  • Makhol_ Discussing Arts E2 with Astad Deboo
  • Society :: Poem
  • IQs & EQs of politicians
  • Living with COVID 19
  • 'Blood donors should be welcome'
  • Bracing for the worst
  • Princess & Political Agent launch #2 : Gallery
  • COVID-19 Status 24 July : Govt of Manipur
  • Virus Fabrics Spray by Kakchingtambam Kiran
  • Tales from a conflict zone :: Poem
  • Why Manipur senior IPS officer shot himself
  • Anti Defection Law: Big Debate
  • COVID-19 vaccine : So near and yet so far
  • Central observers here after trip to Delhi
  • The limitation on Free Speech
  • Impact of COVID-19 on transgender
  • COVID-19 Status 23 July : Govt of Manipur
  • Love Story of Tonu Laijing Lembi
  • 29th NAMA Virtual Convention 2020
  • Understanding disasters & disaster mgmt #2
  • Seeking NHRC to intervent in Akhil Gogoi case
  • Impacts of COVID-19 on agriculture : Paper
  • Lockdown & opening doors to outsiders
  • In search of the elusive leader
  • Anti-Repression Day #2 : Gallery
  • COVID-19 Status 22 July : Govt of Manipur
  • Race Apart ? :: Poem
  • Of political instability, COVID & war on drug
  • Preventing skin damage due to face masks
  • Issues raised by NPF Legislature Wing
  • Webninar : How to develop skills in writings
  • Nonsensical rush for fuel
  • When the virus starts attacking
  • Manipur & the Lushai Expedition, 1871-72 #3
  • COVID-19 Status 21 July : Govt of Manipur
  • Negatives turning positive, catastrophe in wait?
  • Environmental change : Uttarakhand : Rvw
  • Empathy Campaign at Imphal Airport
  • Rejoinder by Dr. Liezietsu [21 Jul]
  • Responsible conduct- Jiribam to Thoubal
  • BJP may be in trouble..
  • The Princess & Political Agent launch : Gallery
  • COVID-19 Status 20 July : Govt of Manipur
  • Governor & Maharani launch Binodini's Book
  • Mount Koubru: Its dying glory, & way forward
  • Govt expenditures on education in Manipur
  • 2nd Online Career counseling in IT
  • The last of the oaks :: Poem
  • Rising cases of infection
  • Manipur today is living on mercy of Delhi
  • HSE Toppers - Commerce stream : Gallery
  • COVID-19 Status 19 July : Govt of Manipur
  • Featured Front Page Photo 2020 #3: Gallery
  • Loktak Lake: A gem perishing front of our eye
  • Man behind 'Save Nambul'
  • X-rays and applications
  • COVID-19 pandemic & existential crisis
  • Training programme on mushroom cultivation
  • Best result in last three years
  • HSE Toppers - Science stream : Gallery
  • COVID-19 Status 18 July : Govt of Manipur
  • Understanding disasters & disaster mgmt #1
  • Salam Sangita : NE Women Success Stories
  • Subconscious Mind in COVID Era :: Poem
  • In quest of leadership
  • 4 BJP Ministers' visit to Delhi
  • HSE Toppers - Arts stream : Gallery
  • COVID-19 Status 17 July : Govt of Manipur
  • Between hospitals and hope
  • War on drugs: A losing battle in Manipur
  • Rays of the Setting Sun :: Poem
  • What actually LOP meant & intended : NPF
  • Rejoinder by Dr. Shurhozelie Liezietsu
  • Posers over Delhi trip
  • The face of justice
  • Class XII Result : Highest Marks
  • Class XII Result : Science Toppers
  • Class XII Result : Arts Toppers
  • Class XII Result : Commerce Toppers
  • Class XII Result : District PC
  • Class XII Result : Science
  • Class XII Result : Arts
  • Class XII Result : Commerce
  • COVID-19 Status 16 July : Govt of Manipur
  • Training programme on mushroom : Gallery
  • Diplomacy in Power & Leadership
  • PPE distributed to Community Health Centre
  • Think population studies as career
  • Intensify agitations as Govt fails to act
  • The Jiribam and Thoubal experience
  • Discovery of Thangjing hill range waterfall
  • Anti-Repression Day #1 : Gallery
  • Accelerating rights of women, post-COVID
  • Heritage Park @ Sangai Festival : Gallery
  • EEVFAM Foundation day : Gallery
  • Mining MoUs & Concerns in Manipur
  • Licypriya low-cost 'Face Shields' : Gallery
  • Airlifting of organic Pineapples : Gallery
  • 9th Manipuri Film Awards (MANIFA) Result
  • Yaoshang Halankar @BijoyGovinda #2: Gallery
  • Manipur & the Lushai Expedition, 1871-72 #2
  • Barak waterfall @ Tamenglong #2 : Gallery
  • Kanglen Aarti katpa #2 : Gallery
  • Eikhoigi Puwarini Nambul Turel #2 : Gallery
  • Manipur & the Lushai Expedition, 1871-72 #1
  • Takhelchangbam Kunjabihari : Wari Liba
  • I Rise :: Film Scenes : eRang
  • Class X (HSLC) Exam Toppers : Gallery
  • Class X Exam 2020 : Merit List
  • Class X Exam 2020 : Result Sheet
  • Class X Exam 2020 : Subject Toppers
  • Class X Exam 2020 : Statistics Abstract
  • Motsillaba Mingsel :: eRang Photos
  • Eyek Tamba :: Learn Manipuri script
  • SPONSORED ADS